Skip to main content

Table 2 Summary of findings including ARIMA models and cross-correlation results between sTNF-R55 concentrations and SLE-specific and SLE-unspecific symptoms

From: Cause-effect relations between 55 kD soluble TNF receptor concentrations and specific and unspecific symptoms in a patient with mild SLE disease activity: an exploratory time series analysis study

  Urinary sTNF-R55, AR(2) SMA(1), s = 14, ln
Urinary protein, (0,0,0), cube root −lag2: r = +0.202; p = 0.033 +lag3: r = −0.213; p = 0.024
Oral ulceration, binary-coded −lag3: r = −0.313; p = 0.001 +lag3: r = +0.277; p = 0.003
Facial rash, binary-coded n.s. +lag3: r = −0.223; p = 0.018
Body temperature, deterministic season, s = 2, ln −lag3: r = +0.209; p = 0.027 n.s.
Weakness, MA(4), ln n.s. n.s.
Fatigue, deterministic trend n.s. n.s.
Joint pain, AR(1), deterministic trend n.s. n.s.
  1. +Lag means that sTNF-R55 levels precede SLE symptom, and –lag means that SLE symptom precedes sTNF-R55 levels
  2. sTNF-R55 soluble tumor necrosis factor 55 kD receptor, AR autoregressive, MA moving average, SMA seasonal moving average, s seasonality, n.s. not significant